# US 2018/0021235 A1 · Methods for treating hair loss disorders > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2018/0021235 A1 - Document ID: US20180021235A1 - Status: Published application - Kind: A1 - Application number: 15/668,814 - Filed: 2017-08-04 - Published: 2018-01-25 - Earliest claimed: 2010-11-02 - Assignees: The Trustees of Columbia University in the City of New York - Applicants: The Trustees of Columbia University In the City of New York - Inventors: Angela M. Christiano; Raphael Clynes - Web page: https://patentgrep.com/patent/US20180021235A1 ## CPC - A61K 31/713: Double-stranded nucleic acids or oligonucleotides - A61Q 7/00: Preparations for affecting hair growth - A61K 8/41: Amines - A61K 8/4953: {containing pyrimidine ring derivatives, e.g. minoxidil} - A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof - A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} - A61K 31/277: having a ring, e.g. verapamil - A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine - A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline - A61K 31/506: not condensed and containing further heterocyclic rings - A61K 31/519: ortho- or peri-condensed with heterocyclic rings - A61K 31/52: Purines, e.g. adenine - A61K 31/529: forming part of bridged ring systems - A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol - A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine - A61K 31/63: Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide - A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides - A61K 2800/782: Enzyme inhibitors; Enzyme antagonists - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS ## Abstract The invention provides for methods for treating a hiar loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor. ## Claims ### Claim 1 A method of treating alopecia areata in a human in need thereof comprising administering to the human an effective amount of the compound: ### Claim 2 (depends on 1) The method of claim 1, wherein the alopecia areata is patchy alopecia areata. ### Claim 3 (depends on 1) The method of claim 1, wherein the alopecia areata is alopecia totalis. ### Claim 4 (depends on 1) The method of claim 1, wherein the alopecia areata is alopecia universalis. ### Claim 5 (depends on 1) The method of claim 1, wherein the effective amount of the compound is administered topically. ### Claim 6 (depends on 1) The method of claim 1, wherein the effective amount of the compound is administered orally. ### Claim 7 (depends on 1) The method of claim 1, wherein administering to the human occurs in a route selected from intra-muscular injection, intra-peritoneal injection, an infusion, intravenous, intradermal, subcutaneous, oral, inhalation, transdermal, topical, transmucosal, nasal and rectal. ### Claim 8 (depends on 1) The method of claim 1, wherein the compound is administered to the human in a pharmaceutical composition selected from a solution, suspension, capsule, tablet, pill, troche, nasal spray, suppository, ointment, salve, gel, and cream. ### Claim 9 (depends on 1) The method of claim 1, wherein administering to the human occurs twice daily, daily, weekly, twice weekly, monthly, twice monthly and yearly. ### Claim 10 (depends on 1) The method of claim 1, wherein the compound includes an isotope. ### Claim 11 (depends on 1) The method of claim 1, wherein the compound includes one or more isotopes of carbon or hydrogen. ### Claim 12 (depends on 1) The method of claim 1, wherein the method further comprises administering a second JAK inhibitor to said human. ### Claim 13 (depends on 1) The method of claim 1, wherein the compound is the sole therapeutically active ingredient administered to said human for treating alopecia areata. ### Claim 14 (depends on 1) The method of claim 1, wherein treating alopecia areata is inducing hair growth. ### Claim 15 (depends on 10) The method of claim 10, wherein the compound is suitable for NMR. ### Claim 16 (depends on 10) The method of claim 10, wherein the isotope is a radioisotope. ### Claim 17 (depends on 10) The method of claim 10, wherein the alopecia areata is patchy alopecia areata. ### Claim 18 (depends on 10) The method of claim 10, wherein the alopecia areata is alopecia totalis. ### Claim 19 (depends on 10) The method of claim 10, wherein the alopecia areata is alopecia universalis. ### Claim 20 (depends on 10) The method of claim 10, wherein the compound is administered topically. ### Claim 21 (depends on 10) The method of claim 10, wherein compound is administered orally. ### Claim 22 (depends on 11) The method of claim 11, wherein the compound is suitable for NMR. ### Claim 23 (depends on 11) The method of claim 11, wherein the isotope is a radioisotope. ### Claim 24 (depends on 11) The method of claim 11, wherein the alopecia areata is patchy alopecia areata. ### Claim 25 (depends on 11) The method of claim 11, wherein the alopecia areata is alopecia totalis. ### Claim 26 (depends on 11) The method of claim 11, wherein the alopecia areata is alopecia universalis. ### Claim 27 (depends on 11) The method of claim 11, wherein the compound is administered topically. ### Claim 28 (depends on 11) The method of claim 11, wherein the compound is administered orally.